Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Supernus Pharmaceuticals ( (SUPN) ) has issued an update.
On November 4, 2025, Supernus Pharmaceuticals announced that due to stronger than expected demand for ONAPGO, supplier constraints are impacting the company’s ability to fully meet this demand. As a result, the company is prioritizing care for patients currently on ONAPGO by pausing delivery to new patients. The company is working to build adequate inventory and resume new patient initiations as soon as possible. Additionally, Supernus reported a 52% increase in combined revenues of its four growth products in the third quarter of 2025, driven by an increase in net sales of Qelbree and GOCOVRI, and the addition of sales from ZURZUVAE and ONAPGO. The company also completed the acquisition of Sage Therapeutics, Inc. on July 31, 2025, and increased its full-year 2025 revenue guidance.
The most recent analyst rating on (SUPN) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.
Spark’s Take on SUPN Stock
According to Spark, TipRanks’ AI Analyst, SUPN is a Outperform.
Supernus Pharmaceuticals receives a strong overall score driven by solid financial performance, positive technical indicators, and a favorable earnings call. The company’s robust cash flow management and low leverage provide a stable financial foundation. The upward trend in stock price and positive market momentum further enhance the outlook. However, the high P/E ratio and lack of dividend yield slightly temper the valuation perspective. The positive earnings call, with increased revenue guidance and successful product launches, significantly contributes to the overall score.
To see Spark’s full report on SUPN stock, click here.
More about Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Average Trading Volume: 827,953
Technical Sentiment Signal: Buy
Current Market Cap: $3.12B
Learn more about SUPN stock on TipRanks’ Stock Analysis page.